Beneath the contract, 3M will donate its patented toll-like receptor immune response modifier compounds. 3M’s patented TLR immune response modifier compounds, which might be useful as vaccine adjuvants, will be used by IDRI to research brand-new vaccines. Vaccine adjuvants are recognized to help boost the effectiveness of a vaccine. Related StoriesBasic analysis for developing toxoplasma vaccine underwayGHIT Fund invests $10.7 million to fight malaria, TB, leishmaniasis and dengueKey component of MRSA vaccine puzzle unearthed’IDRI’s vaccine system has the potential to prevent and treat numerous important illnesses in the developing world. By providing our vaccine adjuvant substances to their vaccines, we are offering a cost-effective way for IDRI to conduct vaccine analysis,’ said Dr.About Visiogen Visiogen, Inc. Is focused on developing innovative products for cataract and refractive sufferers. Founded in 2001 and located in Irvine, Calif., Visiogen’s first commercial application, the Synchrony, a 3-dimensional, dual-optic accommodating intraocular zoom lens and pre-loaded injector, was commercially released in European countries in 2009 2009. The outcomes of the U.S. IDE study, completed in 2009 2009, are under review by the U.S. Food and Drug Administration . More information about Visiogen and the Synchrony accommodating IOL are available at About Abbott Abbott can be a global, broad-based health care company specialized in the discovery, development, advertising and produce of pharmaceuticals and medical products, including nutritionals, diagnostics and devices.